Top 4 Liver Cancer Research Opportunities to Apply for in 2026–2027
Top 4 Liver Cancer Research Opportunities to Apply for in 2026–2027 Oncodaily
Онкология
🎗️Лента новостей
🎗️
Онкология
Natera, Alliance Foundation Trials Launch Phase III Trial for MRD-Guided Treatment in Breast Cancer
Natera, Alliance Foundation Trials Launch Phase III Trial for MRD-Guided Treatment in Breast Cancer Genome Web
Онкология
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer Morningstar
Онкология
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer PR Newswire
Онкология
Cancer Leading Cause of Death Among Hispanic/Latino People; Higher Burden for Largely Preventable Cancers Including Cervical, Liver and Stomach, ACS Report Finds
American Cancer Society researchers stress lack of access to health insurance and screening as barriers to progress
Онкология
El cáncer es la principal causa de muerte entre la población hispana/latina; la carga es mayor en el caso de cánceres en gran medida prevenibles, como el de cuello uterino, hígado y estómago, según un informe de la ACS
Los investigadores de la American Cancer Society destacan que la falta de acceso al seguro médico y a las pruebas de detección son obstáculos para el progreso
Онкология
Over Two Million Reached Through the American Cancer Society and NFL’s Focus on Increasing Cancer Screening
The partnership’s Crucial Catch initiative works to improve cancer outcomes nationwide by addressing access to cancer screening.
Онкология
Phase III Trial Tests Blood-Based MRD Monitoring to Spare Breast Cancer Patients CDK4/6 Inhibitor Toxicity
Phase III Trial Tests Blood-Based MRD Monitoring to Spare Breast Cancer Patients CDK4/6 Inhibitor Toxicity Bioengineer.org
Онкология
ESMO GU Cancers Asia 2027 Brings Global Collaboration to GU Cancer Research
ESMO GU Cancers Asia 2027 Brings Global Collaboration to GU Cancer Research Oncodaily
Онкология
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer BioSpace
Онкология
Cancer research needs greater collaboration, funding: KU VC
Cancer research needs greater collaboration, funding: KU VC KNS News
Онкология
Rasha Aboelhassan: What Truly Makes a Cancer Centre Successful?
Rasha Aboelhassan: What Truly Makes a Cancer Centre Successful? Oncodaily
Онкология
Рак молочной железы занял 19% в структуре онкозаболеваемости в России
Рак молочной железы занял 19% в структуре онкозаболеваемости в России Medvestnik
Онкология
Oncologist views on pharmacogenomic testing and implementation
More than 90% of oncologists who prescribe chemotherapy drugs such as fluoropyrimidines, thiopurines and irinotecan know genetic variants are linked to adverse events, and more than half perform pharmacogenomic testing before prescribing. “This is really encouraging,” Stuart A. Scott, PhD, professor of pathology and…